Xinhua Pharmaceutical: Subsidiary obtains azithromycin dry suspension "Drug Registration Certificate"

Xinhua Pharmaceutical announced that recently, its wholly-owned subsidiary Shandong Zibo Xinda Pharmaceutical Co., Ltd. received the approved and issued "Drug Registration Certificate" for Clarithromycin Dry Suspension by the National Medical Products Administration, approving the registration of the product. This product is used to treat infections caused by pathogens sensitive to clarithromycin, including upper respiratory tract infections, lower respiratory tract infections, skin and soft tissue infections, acute otitis media, etc.